Implementing treatment goals for successful long-term management of psoriasis

Journal of the European Academy of Dermatology and Venereology : JEADV
U Mrowietz

Abstract

Treatment goals are commonly used throughout medicine to ensure efficacious therapy of diseases and to prevent complications related to uncontrolled disease activity, such as the management of hypertension and diabetes. Psoriasis is a systemic immune-mediated inflammatory disease comprising characteristic skin manifestations. A range of co-morbidities has been associated with it, including diabetes and cardiovascular diseases such as myocardial infarction (MI) and stroke. There is good evidence that the severity of skin symptoms is related to mortality associated with MI. Therefore, long-term efficacious control of skin inflammation is the treatment paradigm of choice, particularly in patients with severe skin involvement. Surveys in a number of countries have revealed a substantial under-treatment of patients with moderate-to-severe psoriasis, leaving a considerable proportion without adequate disease control. In addition, a high number of patients were not satisfied with their treatment, including the time they needed to allocate for skin therapy and the number of visits to physicians. Therefore, the use of effective therapies is necessary to achieve appropriate control of inflammation and to improve patient satisfaction. The...Continue Reading

References

Sep 25, 1999·Journal of the American Academy of Dermatology·H L RichardsC E Griffiths
Aug 15, 2003·The New England Journal of Medicine·Vera M R HeydendaelMenno A de Rie
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Feb 5, 2005·Journal of the American Academy of Dermatology·Srdjan ProdanovichRobert S Kirsner
Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Jun 21, 2005·Journal of the American Academy of Dermatology·Steven R FeldmanJerry Bagel
Aug 27, 2005·The British Journal of Dermatology·C H SmithUNKNOWN British Association of Dermatologists
Sep 6, 2005·Arthritis and Rheumatism·Daniel AletahaJosef S Smolen
Oct 21, 2005·International Journal of Clinical Practice·S E Gillard, A Y Finlay
Mar 2, 2006·Arthritis and Rheumatism·Josef S SmolenUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) S
Sep 13, 2006·The British Journal of Dermatology·L DubertretUNKNOWN EUROPSO Patient Survey Group
Oct 13, 2006·JAMA : the Journal of the American Medical Association·Joel M GelfandAndrea B Troxel
May 15, 2007·Archives of Dermatological Research·A NastB Rzany
Jun 20, 2007·Archives of Dermatology·Stephen TyringAngelika Jahreis
Jul 11, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Berufsverband Deutscher Dermatologen (BVDD)
Aug 21, 2007·Journal of the American Academy of Dermatology·Elizabeth J HornMark Lebwohl
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Feb 5, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Jolie J GuttelingRobert A de Man
Mar 6, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·M AugustinK Reich
May 10, 2008·Journal of the American Academy of Dermatology·Andreas StormJørgen Serup
Jul 3, 2008·Annals of the Rheumatic Diseases·J S SmolenUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) S
Sep 20, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Matthias AugustinMarc Radtke
May 26, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Jun 30, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Aug 29, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·D PathiranaB Rzany
Oct 14, 2009·European Journal of Dermatology : EJD·Ines SchäferMatthias Augustin
Oct 28, 2009·The British Journal of Dermatology·C H SmithUNKNOWN (Chair of Guideline Group)
Nov 19, 2009·Journal of Cutaneous Medicine and Surgery·Norman WaselKim Papp
Jan 9, 2010·Annals of the Rheumatic Diseases·D E FurstK Winthrop
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Apr 17, 2010·The British Journal of Dermatology·R G LangleyM M Okun
Jul 17, 2010·The British Journal of Dermatology·K AbuabaraJ M Gelfand
Sep 22, 2010·Archives of Dermatological Research·U MrowietzN Yawalkar
Apr 16, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·U MrowietzK Reich
Jun 23, 2011·JAMA : the Journal of the American Medical Association·Daniel H SolomonSebastian Schneeweiss
Jun 23, 2011·JAMA : the Journal of the American Medical Association·Tim Bongartz, Yogish Kudva

❮ Previous
Next ❯

Citations

Apr 30, 2014·American Journal of Clinical Dermatology·Esther de EusebioVíctor Alegre de Miquel
Jan 30, 2016·The Journal of Dermatological Treatment·Federico BardazziVera Tengattini
May 29, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·L Puig
Nov 6, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·L Puig
Feb 16, 2013·Cytokine·Erine A KupetskyLaura K Ferris
Dec 3, 2016·Journal of the American Academy of Dermatology·April W ArmstrongAbby S Van Voorhees
Mar 17, 2015·Journal of Cutaneous Medicine and Surgery·Wayne GulliverYves Poulin
Apr 21, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·M AugustinI Gilloteau
May 22, 2016·Journal of Cutaneous Medicine and Surgery·Wayne P GulliverPatrick Fleming
Sep 11, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·R G LangleyK Reich
May 1, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·P de la Cueva DobaoL Puig
Feb 25, 2020·The Journal of Dermatological Treatment·Siegfried SegaertMelinda Gooderham
Jan 1, 2015·Archives of Dermatological Research·M A RadtkeMatthias Augustin
May 14, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Matthias Augustin, Marc Alexander Radtke
Oct 30, 2016·The Journal of Dermatological Treatment·Julien LambertMaria Van den Enden
Mar 6, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·R G Langley
Oct 23, 2019·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Daniela Ledić DrvarRomana Čeović
May 5, 2021·The Journal of Dermatological Treatment·Claire BarkPer Svangren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here